Reply to Clarification- Financial results

Date: 30th June, 2026 Place: Hyderabad National Stock Exchange of India Limited Exchange Plaza, Plot No.C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir / Madam, Subject: Clarification on Financial Results submitted on 28th May, 2026 We acknowledge receipt of your email dated 24th June, 2026, regarding discrepancies observed in the Outcome of Board Meeting and XBRL filing of the Financial Results submitted by the Company on 28th May, 2026. In this regard, please find below our response: Query 1 - Standalone PAT not matching in XBRL & PDF: Clarification: a) ‘Employee Benefit Expense’ in the Standalone Financial Results for the Quarter ended 31st March, 2026 has been inadvertently mentioned as INR 229.46 Lakhs instead of INR 229.66 Lakhs in both the PDF version of the Outcome of Board Meeting as well as the Standalone XBRL Filing. b) The 'Total Expense' in the Standalone Financial Results for the Quarter ended 31st March, 2026 is appearing correctly as INR 2319.29 Lakhs in the PDF version of the Outcome of Board Meeting despite Employee Benefit Expense being inadvertently mentioned in the PDF Outcome of Board Meeting as per Point ‘a’ above. On the other hand, the total expense in the Standalone Financial Results for the Quarter ended 31st March, 2026 is incorrectly appearing as INR 2319.09 Lakhs in the Standalone XBRL File instead of INR 2319.29 Lakhs. The difference is due to the mistake mentioned in Point ‘a’ above. Corrective Action taken: a)The Company has filed the revised Standalone Financial XBRL Results incorporating the necessary corrections. b) We are hereby enclosing the Revised PDF Outcome of Board Meeting which was announced on 28th May, 2026 with necessary correction relating to ‘Employee Benefit Expense’ which is part of the Standalone Financial Results for the Quarter ended 31st March, 2026. There is no change in the remaining parts of the PDF Outcome of Board Meeting announced on 28th May, 2026. Query 2 - Consolidated Total Comprehensive Income for the period not matching in XBRL and PDF: Clarification: a)‘Other comprehensive income net of taxes’ in the Consolidated Financial Results for the Quarter ended 31st March, 2026 has been inadvertently mentioned with a minus sign as INR - 844.46 Lakhs instead of positive figure INR 844.46 Lakhs in the Consolidated XBRL Filing, because of which the Total Comprehensive Income for the Quarter ended 31st March, 2026 is appearing in the Consolidated XBRL File with a minus sign as ‘INR -783.17 Lakhs’ instead of positive figure ‘INR 905.74 Lakhs’. b) ‘Other comprehensive income net of taxes’ in the Consolidated Financial Results for the Year ended 31st March, 2026 has been inadvertently mentioned with a minus sign as INR – 1592.31 Lakhs instead of positive figure INR 1592.31 Lakhs in the Consolidated XBRL Filing, because of which the Total Comprehensive Income for the Year ended 31st March, 2026 is appearing in the Consolidated XBRL with a minus sign as ‘-1450.62 Lakhs’ instead of positive figure ‘INR 1734 Lakhs.’ Note: The figures in the PDF Outcome of Board Meeting with respect to Query – 2 is correct as announced on 28th May, 2026 and there is no change with respect to the same. Corrective Action taken: The Company has filed the revised Consolidated Financial XBRL Results incorporating the necessary corrections. Kindly take the above clarification on record. Thanking You. Yours faithfully, For Balaxi Pharmaceuticals Limited Aman Purohit (Company Secretary & Compliance Officer) ICSI Membership No.: A59345 Encl: Revised Outcome of Board Meeting announced on 28th May, 2026. Date: 28.05.2026 Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Outcome of Board Meeting In reference to our letter dated May 09, 2026, we wish to inform you that the Board of Directors at their meeting held today i.e., May 28, 2026, have inter-alia, approved the following: 1. Standalone and Consolidated Audited Financial Results of the Company for the fourth quarter and financial year ended March 31, 2026 Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Standalone and Consolidated Audited Financial Results of the Company for the fourth quarter and financial year ended March 31, 2026, (Enclosed as Annexure – A) accompanied by Audit Report thereon by the Statutory Auditors of the Company. (Enclosed as Annexure – B) 2. Re-appointment of M/s Siva Rama Krishna & Associates, Chartered Accountants as Internal Auditors of the Company. Board of Directors have approved the re-appointment of M/s. Siva Rama Krishna & Associates, Chartered Accountants (Firm registration number: 013342S) as Internal Auditors of the Company for the financial year 2026-27. 3. Recommended for the re-appointment of Ms. Akshita Ostwal (DIN: 10026552) as an Independent Director of the Company. Board of Directors have recommended to the Members for their approval, the re- appointment of Ms. Akshita Ostwal as an Independent Director of the Company for a second term of five consecutive years from September 05, 2026. The approval of the members will be sought in the ensuing 83rd Annual General Meeting (“AGM”) of the Company. Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase Ill, Road No. 81, Jubilee Hills, Hyderabad (T.G.) -500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 I Email: info@balaxi.in I Website: www.balaxipharma.in The additional details in pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 relating to the item no’s 2 & 3 is enclosed as Annexure – C. 4. Took note of the update on the Company’s First Pharmaceuticals Formulation plant, at Jadcherla, Hyderabad The Board of Directors took note of the progress of the Company’s first pharmaceutical formulation manufacturing facility at Jadcherla, Hyderabad, as apprised by the Managing Director. During the quarter, a joint inspection of the facility was conducted by CDSCO. Pursuant to submission of CAPA against the observations raised during the inspection and successful completion of the CAPA verification audit conducted on 27th April 2026, the Company received the Manufacturing Licence for its pharmaceutical formulation facility on 23rd May, 2026. The Board further noted that the Company is now fully prepared for commercialization of Paracetamol Tablet 500mg and Piroxicam Capsule 20mg, and the required raw materials and key input materials have already been received at the facility. Further, Company has initiated the process for obtaining manufacturing product permissions for 40 additional products. This will support phased expansion of the facility’s commercial product portfolio. The Company will continue adding more products to its manufacturing portfolio going forward. The Board was also apprised that the Company is progressing towards WHO-GMP certification for the facility and is in the process of submitting the application with the concerned authorities. The certification process will involve a joint inspection by CDSCO and State FDA under WHO-GMP guidelines and is expected to strengthen the Company’s manufacturing capabilities and support future growth opportunities. The Board expressed satisfaction with the progress achieved and noted that the Company is well positioned for commencement of commercial manufacturing operations and expansion of its formulation business. 5. Annual General Meeting The Board of Directors have approved the notice of the 83rd Annual General Meeting (AGM) of the Company to be held on Monday, 24th August, 2026 through Video Conference/Other Audio Visual Means (VC/OAVM). The Board meeting commenced at 03.00 P.M. (IST) and concluded at 05.00 P.M. (IST). Registered Office: [Showing first 8,000 characters — download PDF for full document]